4% n-Dodecyl β-D- maltoside, n-Dodecyl β-D-maltoside, and 10% Gly

4% n-Dodecyl β-D- maltoside, n-Dodecyl β-D-maltoside, and 10% Glycerol) at room temperature for 30 minutes and the supernatants were separated through centrifugation and used for immunoassay. Statistical Evaluation Statistical analyses Akt inhibitor were performed using independent Student t test or Mann-Whitney U test (GraphPad Software, San Diego California USA,). Differences were considered to be statistically significant for p values ≤ 0.05. Acknowledgements This

work was supported by a grant from Key Special Subjects of Infectious Diseases (2008ZX10002-011 and 2008ZX10002-012) and from the Excellent Youth Foundation of Fujian Scientific Committee (2009J06020). We gratefully acknowledge Lucy Zhu from McGill University for editorial assistance in writing this paper.

We also thank Dr. Hai Yu and Dr. Chenghao Huang (NIDVD, Xiamen) for their technical help with this work. References 1. Lee WM: Protein Tyrosine Kinase inhibitor Hepatitis B virus infection. N Engl J Med 1997,337(24):1733–1745.PubMedCrossRef 2. Beasley RP, Hwang LY, Lin CC, Chien CS: Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan. Lancet 1981,2(8256):1129–1133.PubMedCrossRef 3. Mast EE, Alter MJ, Margolis HS: Strategies to prevent and control hepatitis B and C virus infections: a global perspective. Vaccine 1999,17(13–14):1730–1733.PubMedCrossRef 4. Vial T, Descotes J: Clinical toxicity of the interferons. Drug Saf 1994,10(2):115–150.PubMedCrossRef 5. Fattovich G, Giustina G, Favarato S, Ruol A: A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon. J Hepatol 1996,24(1):38–47.PubMedCrossRef 6. Liaw YF: Antiviral therapy of chronic hepatitis B: opportunities triclocarban and

challenges in Asia. J Hepatol 2009,51(2):403–410.PubMedCrossRef 7. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC: Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998,391(6669):806–811.PubMedCrossRef 8. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T: Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001,411(6836):494–498.PubMedCrossRef 9. Paddison PJ, Caudy AA, Bernstein E, Hannon GJ, Conklin DS: Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells. Genes Dev 2002,16(8):948–958.PubMedCrossRef 10. McCaffrey AP: RNA interference inhibitors of hepatitis B virus. Ann N Y Acad Sci 2009, 1175:15–23.PubMedCrossRef 11. Deng L, Li G, Xi L, Yin A, Gao Y, You W, Wang X, Sun B: Hepatitis B Virus Entospletinib clinical trial Inhibition in Mice by Lentiviral Vector Mediated Small Interference RNA. BMC Gastroenterol 2009,9(1):73.PubMedCrossRef 12. Yang PL, Althage A, Chung J, Chisari FV: Hydrodynamic injection of viral DNA: a mouse model of acute hepatitis B virus infection. Proc Natl Acad Sci USA 2002,99(21):13825–13830.PubMedCrossRef 13.

Comments are closed.